About Ounce Sachs

---

Founded by Ounce Sachs in 2019, MEDUSA is a next-generation surface disinfection platform developed to deliver broad-spectrum bactericidal, fungicidal and virucidal performance.

The technology was designed to provide extended residual surface protection, with testing indicating sustained efficacy against a range of pathogens following application.

Since its inception, MEDUSA has been the subject of commercial development initiatives, regulatory evaluation and market interest across multiple jurisdictions.

In March 2024, MEDUSA became the subject of a commercial transaction involving CS Diagnostics Corp. Certain rights associated with the technology subsequently formed part of contractual arrangements between the parties.

Those arrangements have since become the subject of unresolved contractual disputes, including formal notices relating to alleged breaches and non-performance. Ounce Sachs continues to reserve all rights in relation to MEDUSA and associated intellectual property, technologies and commercial interests.

Notwithstanding these matters, Ounce Sachs remains committed to the continued development, commercialization and advancement of MEDUSA through appropriate commercial and strategic channels.

Ounce Sachs operates a strategy centred on innovation-led, knowledge-based investments, with a focus on identifying and developing differentiated opportunities ahead of broader market consolidation.

The platform maintains an international outlook, with experience across the UAE, US, and Hong Kong, supporting both formulation development and strategic transaction execution.

This approach is characterised by:

Early-stage category identification
Proprietary formulation-led product development
Structured pathways toward strategic partnership, scale, and potential acquisition

The emphasis is not on volume, but on the creation of high-value, defensible assets, positioned for strategic outcomes with aligned partners.

Hygiactivia represents the next application of Ounce Sachs’ formulation-led development model, translating long-duration antimicrobial performance into a premium cosmetic format.

Positioned at the intersection of luxury fragrance and functional personal care, the formulation is designed for repeat daily use, combining sustained residual efficacy with refined fragrance profiles and high-end cosmetic presentation.

Initial production has been intentionally constrained, with early validation demonstrating full sell-through at premium pricing and demand exceeding initial supply. This controlled release has provided proof of positioning, pricing acceptance and market appetite ahead of broader scale.

Building on this foundation, Hygiactivia is now progressing through a structured partner engagement phase, with the objective of aligning with a strategic operator capable of supporting international manufacturing, distribution and brand development.

Based on current positioning and early market response, the opportunity is considered to sit within a multi-million valuation range, with outcomes dependent on partner alignment and execution at scale.

Set within the historic grounds of Château de Veauce in central France, this countryside House will bring together heritage architecture and contemporary Soho House design. The property will feature a collection of bedrooms within the château, alongside club spaces for dining, socialising and cultural programming.

Members will have access to a range of amenities including a wellness and fitness space, outdoor terraces, and landscaped gardens overlooking the surrounding valley. The House will offer a slower-paced retreat from the city, with year-round programming, events and experiences designed around food, art and the local creative community.